Company Overview and News

1
5 Insurers Poised to Outperform Earnings Estimates in Q2

5h zacks
A progressing rate environment, and a strengthening economy have been tailwinds for insurers. With the hike approved by the Federal Reserve in June, marking the sixth increase since December 2016, the rate currently stands at 2%. The second quarter thus continues to enjoy the positive impact of a favorable rate environment, driving the insurer’s investment results as well as the performance of life insurers.
HIIQ TMK TMK

1
A.M. Best Revises Torchmark's (TMK) Outlook, Affirms Ratings

2018-07-12 zacks
Credit rating giant A.M. Best has revised the outlooks for Torchmark Corporation (TMK - Free Report) and its units. The rating agency has affirmed the Long-Term Issuer Credit Ratings (Long-Term ICR) of “a-” and the Long and Short-Term Issue Credit Ratings (Long-Term IR and Short-Term IR) for Torchmark. Simultaneously, A.M. Best revised the outlook for the abovementioned ratings from stable to negative.
NGHCP TMK NGHCO NGHCN TMK.PRC TMK.PRB FAF NGHC TMK NGHCZ

1
7 Insurers Poised to Outperform in Q2 on Many Tailwinds

2018-07-12 zacks
The Finance sector is set to kick off its earnings season this week with major banks reporting quarterly results. Improving rate environment and tax cuts should continue to drive the sector’s performance. Per the Earnings Outlook, earnings for the sector are expected to increase 18.5% on 3.6% higher revenues. Insurers, an important component of the Finance sector, are shortly going to release their financial numbers.
UNM TMK TRV SLF PGR TMK CNO SLF ALL MFC MFC CB

3
Sell Tesla: Wall Street pulls out the rarest of ratings for Elon Musk

2018-07-07 nzherald.co.nz
Elon Musk is on Twitter scolding news organisations for quoting analysts with a bearish view of Tesla Inc. There are a lot to choose from.
UA TMK TMK.PRC TMK.PRB UAA AAPL ED TMK

3
Sell Tesla: Wall Street Pulls Out the Rarest of Ratings for Musk - Bloomberg

2018-07-06 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
UA TMK TMK.PRC TMK.PRB UAA AAPL ED TMK

0
TMK / Torchmark Corp. S-8 AIL EE 401(K) PROFIT SHARIING PLAN

2018-06-29 sec.gov
Document As Filed with the Securities and Exchange Commission on June 29, 2018
TMK

5
Why You Should Retain Torchmark (TMK) in Your Portfolio

2018-06-28 zacks
Estimates for Torchmark Corporation (TMK - Free Report) have been revised upward over the past 60 days, reflecting analysts’ confidence in the stock. The stock has seen the Zacks Consensus Estimate for 2018 earnings being raised 0.2% to $6.04. This provider of annuities, whole and term life insurance, accidental death insurance, health insurance, Medicare supplements and long-term healthcare policies carries a favorable VGM Score of B.
TMK TMK.PRC TMK.PRB GM.WS.A GM.WS.B GM.WS.C GWGH GM TMK GM.WSB Y

720
Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q1 2018 Update

2018-05-16 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to Berkshire Hathaway’s (NYSE:BRK.A) (NYSE:BRK.B) 13F stock portfolio on a quarterly basis. It is based on Warren Buffett’s regulatory 13F Form filed on 05/15/2018. Please visit our Tracking 10 Years Of Berkshire Hathaway's Investment Portfolio article series for an idea on how his holdings have progressed over the years and our previous update for the moves in Q4 2017.
LBTY PSX TEVA THI UAL WMT QSR.WI SIRI SHLD MLUSG LBTYK LILAB GM.WS.A GM.WS.B GM.WS.C SRG.PRA BAC BKW UPS AAL USGPF MDLZ SYF TMK BRK.A BK JNJ LILAK VZ GM.WSB BATRA LSXMB WFCNP TMK BATRK PG LSXMA WFC.PRL MTB BATRR AXP WFC.PRJ MCO VZA STOR BAC USB WFC.PRT GS CHTR WFC.PRR TMK.PRC WFC.PRQ TMK.PRB WFC.PRP WFC.PRO WFC.PRN AAPL MON KO BATRB GM USG WFC.PRY QSR WFC.PRX DVA DAL WFC.PRW WFC.PRV LUV IBM WFC WFC.WS FWONB COST LBTYB VRSN AXTA MA LBTYA SNY FWONA V SRG KHC FWONK LSXMK LILA

4
Primerica (PRI) Q1 Earnings Miss Estimates, Improve Y/Y

2018-05-10 zacks
Primerica, Inc. (PRI - Free Report) reported first-quarter 2018 operating income of $1.47 per share, missing the Zacks Consensus Estimate of $1.49 by nearly 1.3%. However, the bottom line improved 32.4% year over year on lower effective tax rate (from the legislation of the Tax Cuts and Jobs Act of 2017). Also, ongoing share buybacks offered an additional upside to the bottom line.
TMK LNC TMK.PRC TMK.PRB PRI RGA LNC.WS TMK

10
Sun Life's (SLF) Q1 Earnings Up on Solid Segmental Growth

2018-05-09 zacks
Sun Life Financial Inc. (SLF - Free Report) reported first-quarter 2018 underlying net income of $609 million (C$770 million), up 14.5% year over year. This improvement was fueled by interest on par seed capital, strong business growth, the lower U.S. income tax rate and favorable investment experience.
TMK SLF LNC.WS TMK SLF LNC TMK.PRC TMK.PRB GM.WS.A GM.WS.B RGA GM.WS.C SLF.PR.G SLFYF GM GM.WSB SLF.PR.B SLF.PR.E SLF.PR.D SLF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to TMK / Torchmark Corp. on message board site Silicon Investor.

Trimark Oil and Gas(V.Tmk)
CUSIP: 891027104